Additionally, in vivo therapeutic effectiveness of trastuzumab-AuNP-111ln was also assessed by intratumorally injecting 10 MBq (≈270 μCi) of radiopharmaceutical into subcutaneous HER2-overexpressing BC xenografts. The gene discussed is ERBB2; the disease is breast cancer.